Arch Therapeutics, developer of the AC5 bleeding control product, announced on Wednesday that Dr. Avtar Dhillon is the new chairman of its board of directors. Dr. Arthur Rosenthal was also named as the company's director, while Dr. Terrence W. Norci is named as its new president and chief executive officer.

Dr. Dhillon previosuly held the position of board director of Arch Biosurgery. He also worked as the president and chief executive officer of Inovio Pharmaceuticals Inc. He also served as chairman of Inovio, where he spearheaded the company's turnaround through his plans of restructuring and acquisition of many technology firms in the European and North American market.

Dr. Rosenthal has almost 40 years of experience in the field, inlcuding senior research and product development roles on a number of healthcare companies. He also brings his knowledge in commercialization and marketing of products to Arch Therapeutics, according to a statement by the company.